Inclusion Criteria:~* Male or female~* 50 years of age or older~* Residing in the community at baseline
(includes assisted living facilities, but excludes long-term care nursing facilities)~* MMSE (Mini-Mental State
Examination) at screen of 14-26 (inclusive)~* No medical contraindications to study participation~* Fluent in
English or Spanish~* Corrected vision and hearing sufficient for compliance with testing procedures~*
Supervision available for study medication~* Caregiver/study partner to accompany participant to all visits~*
Study partner must have direct contact with the participant more than 2 days/week~* Able to ingest oral
medication~* Daily DHA consumption less than or equal to 200 mg/day in prior two months estimated by an
abbreviated DHA food frequency questionnaire~* Neuroimaging consistent with the diagnosis of AD at some time
after the onset of the memory decline~* Clinical laboratory values must be within normal limits or, if
abnormal, must be judged to be clinically insignificant by the investigator~* Stable use of cholinesterase
inhibitors and memantine is permitted if doses are stable for 4 months prior to enrollment~
